---
figid: PMC7215321__ijms-21-02980-g001
figlink: pmc/articles/PMC7215321/figure/ijms-21-02980-f001/
number: F1
caption: 'Targeted therapeutics and immunotherapy used in the treatment of melanoma
  patients. Melanoma cells exert hyperactivation of the RAS/RAF/MEK/ERK signaling
  pathway that regulates different cellular programs, including survival. Targeted
  therapeutics (shown in green background) inhibit activity of either mutated BRAF
  (BRAF*, V600E is the most frequent amino acid substitution) or MEK1/2. BRAFi and
  MEKi are used as a combinatory treatment regimen. Immunotherapy (shown in yellow
  background) includes checkpoint inhibitors: antibodies blocking either PD-1 (programmed
  death-1) or CTLA4 (cytotoxic T-lymphocyte associated protein 4). Both targets for
  immunotherapy are physiological inhibitors of T cell-mediated immune response. RTK,
  receptor tyrosine kinase.'
pmcid: PMC7215321
papertitle: Non-Apoptotic Cell Death Signaling Pathways in Melanoma.
reftext: Mariusz L. Hartman. Int J Mol Sci. 2020 Apr;21(8):2980.
pmc_ranked_result_index: '18340'
pathway_score: 0.9434276
filename: ijms-21-02980-g001.jpg
figtitle: Targeted therapeutics and immunotherapy used in the treatment of melanoma
  patients
year: '2020'
organisms: Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7215321__ijms-21-02980-g001.html
  '@type': Dataset
  description: 'Targeted therapeutics and immunotherapy used in the treatment of melanoma
    patients. Melanoma cells exert hyperactivation of the RAS/RAF/MEK/ERK signaling
    pathway that regulates different cellular programs, including survival. Targeted
    therapeutics (shown in green background) inhibit activity of either mutated BRAF
    (BRAF*, V600E is the most frequent amino acid substitution) or MEK1/2. BRAFi and
    MEKi are used as a combinatory treatment regimen. Immunotherapy (shown in yellow
    background) includes checkpoint inhibitors: antibodies blocking either PD-1 (programmed
    death-1) or CTLA4 (cytotoxic T-lymphocyte associated protein 4). Both targets
    for immunotherapy are physiological inhibitors of T cell-mediated immune response.
    RTK, receptor tyrosine kinase.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CTLA4
  - PDCD1
  - HRAS
  - KRAS
  - NRAS
  - BRAF
  - MAP2K2
  - MAPK3
  - MAPK1
  - vemurafenib
  - dabrafenib
  - encorafenib
  - trametinib
  - cobimetinib
  - binimetinib
  - melanoma
genes:
- word: CTLA4
  symbol: CTLA4
  source: hgnc_symbol
  hgnc_symbol: CTLA4
  entrez: '1493'
- word: PD-1
  symbol: PD-1
  source: hgnc_alias_symbol
  hgnc_symbol: PDCD1
  entrez: '5133'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: BRAF*
  symbol: BRAF
  source: hgnc_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: (MEK1/2
  symbol: MEK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: ERK1/2migration
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
chemicals:
- word: vemurafenib
  source: MESH
  identifier: C551177
- word: dabrafenib
  source: MESH
  identifier: C561627
- word: encorafenib
  source: ''
  identifier: ''
- word: trametinib
  source: MESH
  identifier: C560077
- word: cobimetinib
  source: MESH
  identifier: C574276
- word: binimetinib
  source: MESH
  identifier: C581313
diseases:
- word: melanoma
  source: MESH
  identifier: D008545
figid_alias: PMC7215321__F1
redirect_from: /figures/PMC7215321__F1
figtype: Figure
---
